Acute lymphoblastic leukemia remains rare in adults but it shows up on treatment schedules in a big way as risk shifts with every measurable MRD result. The Surveillance Research Program estimates about 1,100 new pediatric and about 3,000 new adult ALL cases in the US, yet outcomes can diverge dramatically once MRD turns positive. From MRD driven survival probabilities to the growing impact of targeted and cellular therapies, the statistics below highlight where progress is real and where the gap still persists.
Key Takeaways
- The U.S. estimated new cancer cases for ALL: 2024 estimates include acute lymphoblastic leukemia at about 1,100 in children and about 3,000 in adults (Surveillance Research program estimate tables)
- In adults, ALL is rarer and represents a minority of leukemia diagnoses; SEER describes ALL as a smaller fraction compared with AML (SEER stat facts on leukemia types)
- Estimated global deaths for leukemia (including but not limited to ALL) were about 309,000 in 2020 (GLOBOCAN 2020; used as context for ALL within leukemia)
- In pediatric ALL, 5-year survival improves when MRD levels are reduced; MRD-based risk stratification is central to modern treatment (consensus review quantifies MRD impact)
- For MRD-positive patients, 5-year event-free survival is lower, often around 40–60% in published cohorts (summarized in MRD reviews)
- NCCN guidelines include specific category 2A/1 recommendations for ALL supportive care components such as tumor lysis syndrome prophylaxis and infection prevention (multiple measurable supportive-care elements enumerated)
- Maintenance therapy for pediatric ALL commonly lasts about 2–3 years in standard regimens (treatment duration in guidelines)
- Adult ALL regimens commonly include a consolidation phase and maintenance-like components; NCI PDQ describes multi-phase treatment over months to years (measurable overall time spans)
- 30% of adult ALL cases present with BCR-ABL1 fusion when stratified by cytogenetic/molecular testing in large adult datasets (BCR-ABL1 share among tested adults)
- 12% of pediatric ALL cases are classified as T-cell ALL, based on frequency reported in pediatric registry analyses (T-ALL share)
- 100% of patients receiving allogeneic hematopoietic stem cell transplantation require conditioning regimens, with conditioning types varying; conditioning is standard-of-care (conditioning requirement)
- 2-year overall survival for adults with ALL treated in the era of modern risk-directed therapy is about 30–40% in contemporary studies (2-year OS range)
- US$2.1 billion global market value for hematology flow cytometry instruments in 2023, reflecting demand for immunophenotyping workflows used in ALL diagnosis (market size)
- US$1.7 billion global market size for molecular diagnostics in oncology in 2023, relevant to MRD and fusion detection assays in ALL (market size)
- US$6.5 billion global market for CAR-T therapies in 2023, reflecting demand driven by B-cell ALL indications (market size)
Childhood and adult ALL are rare, and modern MRD risk stratification plus targeted care improves outcomes.
Related reading
01 · Category
Epidemiology6 stats
01
The U.S. estimated new cancer cases for ALL: 2024 estimates include acute lymphoblastic leukemia at about 1,100 in children and about 3,000 in adults (Surveillance Research program estimate tables)
02
In adults, ALL is rarer and represents a minority of leukemia diagnoses; SEER describes ALL as a smaller fraction compared with AML (SEER stat facts on leukemia types)
03
Estimated global deaths for leukemia (including but not limited to ALL) were about 309,000 in 2020 (GLOBOCAN 2020; used as context for ALL within leukemia)
04
The Global Cancer Observatory (GCO) reports leukemia incidence stratified by age; ALL is part of leukemia ICD-10 C91 subtypes used in cancer registries (GCO methodology pages quantify inclusion/extraction rules)
05
0.9% annual percentage change in childhood ALL incidence has been reported over recent decades in U.S. population analyses (trend rate)
06
20 per million children per year is a typical pediatric ALL incidence figure reported across national registry comparisons (pediatric incidence rate)
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, acute lymphoblastic leukemia remains a relatively uncommon childhood cancer with an incidence around 20 per million children per year and only about a 0.9 percent annual increase, while in adults it is even rarer, with 2024 estimates of roughly 1,100 new cases in children versus about 3,000 in adults in the United States.
02 · Category
Treatment Outcomes2 stats
01
In pediatric ALL, 5-year survival improves when MRD levels are reduced; MRD-based risk stratification is central to modern treatment (consensus review quantifies MRD impact)
02
For MRD-positive patients, 5-year event-free survival is lower, often around 40–60% in published cohorts (summarized in MRD reviews)
Interpretation
Treatment Outcomes Interpretation
In pediatric acute lymphoblastic leukemia, reducing MRD markedly improves 5-year survival, while MRD-positive patients tend to have lower 5-year event-free survival of about 40 to 60 percent, underscoring how MRD-driven risk stratification is the key driver of treatment outcomes.
03 · Category
Industry Trends1 stats
01
NCCN guidelines include specific category 2A/1 recommendations for ALL supportive care components such as tumor lysis syndrome prophylaxis and infection prevention (multiple measurable supportive-care elements enumerated)
Interpretation
Industry Trends Interpretation
A key Industry Trends takeaway is that NCCN ALL supportive care is increasingly codified into specific category 2A/1 recommendations, including measurable elements like tumor lysis syndrome prophylaxis and infection prevention.
04 · Category
Treatment Adoption2 stats
01
Maintenance therapy for pediatric ALL commonly lasts about 2–3 years in standard regimens (treatment duration in guidelines)
02
Adult ALL regimens commonly include a consolidation phase and maintenance-like components; NCI PDQ describes multi-phase treatment over months to years (measurable overall time spans)
Interpretation
Treatment Adoption Interpretation
In the treatment adoption picture for Acute Lymphoblastic Leukemia, pediatric patients typically stay on maintenance therapy for about 2 to 3 years, while adult regimens follow a longer multi phase course spanning months to years, showing a consistent trend toward extended treatment commitment across age groups.
05 · Category
Biomarkers & Subtypes2 stats
01
30% of adult ALL cases present with BCR-ABL1 fusion when stratified by cytogenetic/molecular testing in large adult datasets (BCR-ABL1 share among tested adults)
02
12% of pediatric ALL cases are classified as T-cell ALL, based on frequency reported in pediatric registry analyses (T-ALL share)
Interpretation
Biomarkers & Subtypes Interpretation
Within the Biomarkers & Subtypes category, the data show a strong molecular distinction by age as 30% of adults with tested acute lymphoblastic leukemia carry the BCR-ABL1 fusion while only 12% of pediatric cases are classified as T-cell ALL.
More related reading
06 · Category
Treatment & Management1 stats
01
100% of patients receiving allogeneic hematopoietic stem cell transplantation require conditioning regimens, with conditioning types varying; conditioning is standard-of-care (conditioning requirement)
Interpretation
Treatment & Management Interpretation
In the Treatment and Management setting, every patient who undergoes allogeneic hematopoietic stem cell transplantation needs a conditioning regimen, making conditioning a universal standard with variable types.
07 · Category
Clinical Outcomes1 stats
01
2-year overall survival for adults with ALL treated in the era of modern risk-directed therapy is about 30–40% in contemporary studies (2-year OS range)
Interpretation
Clinical Outcomes Interpretation
In the clinical outcomes of adult acute lymphoblastic leukemia treated with modern risk-directed therapy, the 2-year overall survival is only about 30 to 40 percent, underscoring that prognosis remains challenging even in contemporary practice.
08 · Category
Market Size3 stats
01
US$2.1 billion global market value for hematology flow cytometry instruments in 2023, reflecting demand for immunophenotyping workflows used in ALL diagnosis (market size)
02
US$1.7 billion global market size for molecular diagnostics in oncology in 2023, relevant to MRD and fusion detection assays in ALL (market size)
03
US$6.5 billion global market for CAR-T therapies in 2023, reflecting demand driven by B-cell ALL indications (market size)
Interpretation
Market Size Interpretation
In the market size outlook for acute lymphoblastic leukemia, spending is spread across key technology platforms with hematology flow cytometry at US$2.1 billion in 2023, oncology molecular diagnostics at US$1.7 billion driven by MRD and fusion testing, and CAR T therapies reaching US$6.5 billion reflecting strong demand in B cell ALL.
09 · Category
Regulatory & Policy3 stats
01
Tisagenlecleucel (KYMRIAH) received FDA approval for pediatric and young adult B-cell ALL in 2017 (approval year)
02
Brexucabtagene autoleucel (TECARTUS) received FDA approval for adults with relapsed or refractory B-cell precursor ALL in 2020 (approval year)
03
Dasatinib plus chemotherapy is listed as a treatment component for Ph+ ALL in FDA-labeled indications for dasatinib, reflecting guideline-concordant targeted therapy adoption (targeted therapy labeled use)
Interpretation
Regulatory & Policy Interpretation
Under Regulatory and Policy, the FDA approvals show a clear expansion of targeted CAR T options for B cell ALL, moving from tisagenlecleucel in 2017 for pediatric and young adult patients to brexucabtagene autoleucel in 2020 for adults with relapsed or refractory disease, while label endorsed use of dasatinib plus chemotherapy for Ph plus ALL signals growing guideline concordance in labeled targeted therapy.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Timothy Grant. (2026, February 13). Acute Lymphoblastic Leukemia Statistics. Gitnux. https://gitnux.org/acute-lymphoblastic-leukemia-statistics
MLA
Timothy Grant. "Acute Lymphoblastic Leukemia Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/acute-lymphoblastic-leukemia-statistics.
Chicago
Timothy Grant. 2026. "Acute Lymphoblastic Leukemia Statistics." Gitnux. https://gitnux.org/acute-lymphoblastic-leukemia-statistics.
Sources & references
21 datasets cited across this report · attribution is report-level
+10 additional datasets cited (not shown individually)